Shoshana Shendelman, Applied Therapeutics CEO

Ap­plied Ther­a­peu­tics says rare dis­ease drug fails PhI­II tri­al, still plans to seek ap­proval

Ap­plied Ther­a­peu­tics, which is de­vel­op­ing a treat­ment for a rare dis­ease that af­fects chil­dren who can’t process a sug­ar called galac­tose, missed the pri­ma­ry end­point …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.